Kojic Acid for Skin: Benefits, Pigment Studies and Allergy Risk
Start with our pillar guide: What Is the Skin Barrier? The Science of Hydration, Ceramides and Occlusives, or browse all Skincare Fundamentals articles.
Kojic acid for skin is a fungal tyrosinase inhibitor used to fade melasma and dark patches. Most human trials we reviewed test it in combinations rather than alone, and they are small and short. Reviews treat it as an alternative or add-on to hydroquinone-based treatment, and it can cause contact allergy.
Evidence: Moderate for melasma, mostly in combination products in the trials we reviewed.
Key takeaways
- A 2023 meta-analysis of 45 efficacy studies with 2,359 patients across all topical agents found kojic acid lowered melasma scores, with a 5.3% irritation rate for kojic acid in its 55-study all-agent safety data (Chang et al., 2023).
- In a 12-week split-face trial of 40 Chinese women, more than half of melasma cleared in 60% with added 2% kojic acid and 47.5% without it (Lim, 1999).
- In a 30-person split-face pilot, 5% alpha-arbutin plus 2% kojic acid showed no significant difference from triple combination cream on 2 of 3 effectiveness measures (Tantanasrigul et al., 2025).
- In a Japanese patch-test study, 5 of 8 kojic acid users with suspected cosmetic dermatitis reacted to kojic acid (Nakagawa et al., 1995).
- A 2010 expert panel concluded that kojic acid is safe in cosmetics up to a level below 1% (Burnett et al., 2010).
- A 2026 Delphi consensus of 38 dermatologists, funded by Galderma India, named supervised hydroquinone-based triple combination cream the gold standard and kojic acid an alternative (Sarkar et al., 2026).
What does kojic acid for skin do?
Kojic acid for skin blocks tyrosinase, the enzyme that drives melanin production. This mechanism explains why it might fade pigment, but it can't show how much a cream will change your skin.
Kojic acid is a fungal metabolic product (Nakagawa et al., 1995) linked to Aspergillus fungi (Lim, 1999). A 2022 review reports that it enters cells, binds the active site of tyrosinase, regulates factors involved in melanin production and scavenges free radicals (Zilles et al., 2022). If you already use several actives, our skincare routine order guide explains how products are usually sequenced.
The ingredient has grown popular in over-the-counter skin care for melasma and hyperpigmentation (Zachary et al., 2020). It also has formulation problems. A 2026 narrative review lists poor chemical stability, hydrophilicity (being water-loving) and adverse effects as limits on its efficacy (Elbekbashy et al., 2026). That review reports that nanocarriers, tiny delivery particles, are being developed to address these limits, but it also says they lack clinical validation. Evidence: Lab / animal only for mechanism; human results below.
What are the kojic acid benefits?
The main reported benefits are lower melasma scores in pooled before-and-after data and a relatively low reported irritation rate. Other proposed benefits, such as antioxidant and anti-inflammatory activity, are not established as skin results in people.
A 2023 systematic review of 174 randomized or controlled trials gave kojic acid a grade A recommendation for melasma, alongside hydroquinone, triple combination creams, sunscreens and azelaic acid (Sarkar et al., 2023). The authors declared no conflicts. A separate review of 80 papers found kojic acid effective as an adjuvant, or add-on, therapy with minimal side effects (González-Molina et al., 2022). Its authors also reported no relevant conflicts.
A 2025 review found meaningful pigment reduction and a better safety profile for natural agents including kojic acid, and it suggested a possible role in maintenance therapy (Suliman et al., 2025). Its abstract gives no study count for kojic acid, and funding is not reported in the abstract.
Not every review highlights it. A 2018 systematic review of 30 clinical studies included kojic acid, but its abstract does not name kojic acid among the natural ingredients that showed efficacy (Hollinger et al., 2018). That review had no funding and declared no conflicts.
A 2022 review also lists antioxidant, antimicrobial and anti-inflammatory activity for kojic acid and its derivatives (Zilles et al., 2022). Its abstract doesn't separate lab findings from human results, so these are not proven skin benefits. Its reports of toxicity to cancer cell lines come from lab work and say nothing about treating cancer in people. Evidence: Moderate for melasma; other benefits unproven in human skin.
Does kojic acid for skin work on melasma?
Probably, based on pooled before-and-after data and combination trials, though the size of the effect varies and is often hard to credit to kojic acid alone. Melasma causes brown patches on sun-exposed skin, commonly the face (Sarkar et al., 2023).
The largest pooled data come from a 2023 meta-analysis (Chang et al., 2023). It compared scores before and after treatment using MASI or mMASI, standard measures of melasma severity. Results were reported as a standardized mean difference (SMD), a unit-free measure of effect size. Kojic acid scored -0.9 (95% CI -1.3 to -0.5), and the authors described its efficacy as comparable with hydroquinone at -1.3. Funding was not reported in the abstract.
The best evidence that kojic acid adds something comes from a 1999 randomized split-face trial (Lim, 1999). All 40 women used a gel with 10% glycolic acid and 2% hydroquinone, and 1 side of the face also got 2% kojic acid. Both sides improved, and the 2 complete clearances occurred on the kojic acid side.
Among the trials we reviewed, the closest thing to a standalone test is less impressive. In an open-label randomized trial of 72 Indian women, 2% kojic acid cream used nightly for 16 weeks cut mMASI by 10%, while 5% cysteamine cut it by 12.25% (Patil et al., 2025). The difference wasn't significant, and there was no placebo group. Glenmark Pharmaceuticals supplied study materials and helped with data analysis and manuscript preparation. Four authors were Glenmark employees, and another worked for Mascot Spincontrol India.
| Lim, Dermatol Surg, 1999 | 40 Chinese women | 12 weeks | 10% glycolic acid + 2% hydroquinone gel, with or without 2% kojic acid | More than half cleared in 60% with kojic acid vs 47.5% without |
| Patil et al., Cureus, 2025 | 72 women | 16 weeks | 2% kojic acid vs 5% cysteamine cream, once nightly | mMASI -10% vs -12.25%; difference not significant |
| Tantanasrigul et al., J Cosmet Dermatol, 2025 | 30 | 12 weeks + 4-week follow-up | 5% alpha-arbutin + 2% kojic acid vs triple combination cream | No significant difference in melanin index or mMASI; physician scores improved only with triple combination |
| Park et al., Dermatol Ther, 2022 | 25 | 5 sessions every 2 weeks + 4-week follow-up | Low-fluence Q-switched 1064-nm Nd:YAG laser with or without a tranexamic acid, niacinamide and kojic acid mix | Greater improvement with laser plus topical mix |
Lim, Dermatol Surg, 1999
Result: More than half cleared in 60% with kojic acid vs 47.5% without
Randomized split-face trial. Redness, stinging and exfoliation occurred on both sides and settled by week 3. Funding not reported in abstract. Evidence: Limited.
Patil et al., Cureus, 2025
Result: mMASI -10% vs -12.25%; difference not significant
Open-label randomized trial with no placebo group. Glenmark provided materials and analysis support; 4 authors were Glenmark employees and 1 worked for Mascot Spincontrol India. Evidence: Early / preliminary.
Tantanasrigul et al., J Cosmet Dermatol, 2025
Result: No significant difference in melanin index or mMASI; physician scores improved only with triple combination
Evaluator-blinded split-face randomized pilot. Recurrence was more severe on the triple combination side. No conflicts declared. Evidence: Early / preliminary.
Park et al., Dermatol Ther, 2022
Result: Greater improvement with laser plus topical mix
Single-center prospective split-face trial. Kojic acid strength and funding not reported in abstract. Evidence: Early / preliminary.
MASI and mMASI are melasma severity scores. Of the trials in this table, only Patil tested kojic acid as the sole active in a treatment arm.
The laser trial in the table used a mix of 3 ingredients, so it can't isolate kojic acid's effect (Park et al., 2022). Evidence: Moderate.
Does kojic acid for skin help other dark spots?
We can't say. No trial in the abstracts we reviewed tests kojic acid alone on sun spots or post-inflammatory hyperpigmentation, the dark marks left after skin inflammation.
A 2020 review covers kojic acid among 10 cosmeceuticals for melasma, post-inflammatory hyperpigmentation and solar lentigines, or sun spots (Searle et al., 2020). Its abstract gives no kojic-specific result for any of these conditions. Treat product claims about age spots or acne marks as unproven by the studies we reviewed.
For other brightening options, see our guides to vitamin C for hyperpigmentation and glutathione for skin. Evidence: Limited.
Kojic acid vs hydroquinone vs arbutin: which has better evidence?
Hydroquinone has the strongest standing, kojic acid is a recognized alternative or add-on, and arbutin has the thinnest evidence in the abstracts we reviewed. No trial in the abstracts we reviewed compares all 3 head to head.
Hydroquinone, alone or with a retinoid and corticosteroid in triple combination cream, is the preferred first-line melasma treatment (Patil et al., 2025). A 2022 review calls triple combination the gold standard (González-Molina et al., 2022), and the 2026 consensus agrees but specifies regulated, supervised use (Sarkar et al., 2026).
| Feature | Kojic acid | Hydroquinone | Arbutin |
|---|---|---|---|
| What it is | Fungal tyrosinase inhibitor (Lim) | Conventional first-line melasma agent (Sarkar 2023) | Compound of hydroquinone and glucose (Boo) |
| Standing | Alternative in the 2026 consensus (Sarkar 2026) | Triple combination is the gold standard (Sarkar 2026) | Showed efficacy in a natural-ingredient review (Hollinger) |
| Pooled melasma effect (SMD) | -0.9 (Chang) | -1.3 alone; -1.4 in combinations (Chang) | Not reported in the abstract |
| Irritation data | 5.3% (Chang) | 50.9% for combinations; monotherapy not reported in the abstract (Chang) | Dermatitis described as rare, with no rate given (Boo) |
| Main concern | Contact allergy (Nakagawa) | Irritation, redness, dryness and exogenous ochronosis, a skin discoloration (Patil) | Possible breakdown into hydroquinone (Boo) |
The SMD figures don't come from direct comparisons, because they reflect before-and-after changes pooled across separate studies. The authors did conclude that non-hydroquinone agents other than zinc sulfate may be alternatives to hydroquinone-containing treatments (Chang et al., 2023).
In the abstracts we reviewed, the nearest thing to a direct test used kojic acid and arbutin together; the reviews' reference lists cite older studies comparing kojic acid products with hydroquinone that we didn't assess. In the 30-person pilot, a 5% alpha-arbutin and 2% kojic acid cream showed no significant difference from triple combination cream on melanin index (p = 0.268) and mMASI (p = 0.344), which in a pilot this small doesn't show the two are equivalent (Tantanasrigul et al., 2025). Physician global scores improved only on the triple combination side (p = 0.032). That side also had more redness and stinging and more severe recurrence after treatment stopped.
Arbutin carries its own question. A 2021 review advises caution with arbutin products because hydroquinone may be generated during use (Boo, 2021). A lab paper states that arbutin breaks down into hydroquinone and p-benzoquinone under temperature stress, UV light or acidic dilution, and it notes that these conditions can induce skin toxicity (Khadivi et al., 2024). That study measured chemistry, not skin outcomes in people.
Enzyme data favor alpha-arbutin over natural arbutin, with inhibition of human tyrosinase at 2.0 mM compared with more than 30 mM (Saeedi et al., 2021). The same review also states that studies have shown alpha-arbutin to be 10 times more effective than natural arbutin. The enzyme figures are lab data, and the abstract doesn't say what the 10-times figure is based on, so neither shows how big any difference would be on your face. Evidence: Limited for direct comparisons.
Does kojic acid for skin cause irritation or contact allergy?
Yes, both are possible. Irritation is reported at a relatively low rate in pooled data, while contact allergy, an immune reaction to a substance touching the skin, can appear after months of use.
Show data table
| Agent | Irritation incidence (%) |
|---|---|
| Hydroquinone-containing combinations | 50.9% |
| Cysteamine | 42.2% |
| Azelaic acid | 18.7% |
| Kojic acid | 5.3% |
| Tranexamic acid | 0.8% |
Those pooled rates come from different study populations and formulas (Chang et al., 2023). Trial results also vary. Redness, stinging and exfoliation appeared on both sides of the face in the Lim trial and settled by week 3, so the hydroquinone and glycolic acid base may have contributed (Lim, 1999). The Patil trial reported no adverse effects with 2% kojic acid cream (Patil et al., 2025).
The clearest allergy signal comes from Japan. Between October 1992 and September 1993, researchers patch-tested 220 women with suspected cosmetic-related contact dermatitis (Nakagawa et al., 1995). Of the 8 who had used kojic acid products, 5 reacted to kojic acid and to their own products containing 1% kojic acid. All 212 women who had never used these products tested negative.
Those 5 women, aged 34 to 58, developed facial dermatitis 1 to 12 months after starting the products. The authors concluded that kojic acid has high sensitizing potential. However, every participant already had suspected cosmetic dermatitis, so 5 of 8 doesn't tell you how often allergy occurs among all users. Funding was not reported in the abstract.
The Cosmetic Ingredient Review (CIR) Expert Panel's 2010 assessment is more nuanced than a single "safe" number (Burnett et al., 2010). It says human sensitization data supported 2% in leave-on cosmetics. It then concludes that sensitization and skin lightening would not be seen below 1%, and that kojic acid is safe in cosmetics up to that level. So the level it calls safe is one where it expected no lightening, while 3 of the main trials above used 2%.
The same assessment says some animal data suggested tumor promotion and weak carcinogenicity. It adds that kojic acid is slowly absorbed into the circulation from human skin and likely would not reach the threshold at which those effects were seen. A 2022 review calls kojic acid and its derivatives safe for human use at the concentrations tested (Zilles et al., 2022). Evidence: Limited for allergy frequency; Lab / animal only for the tumor signal.
How are kojic acid products used in studies?
The trials we reviewed usually tested 2% kojic acid for 12 to 16 weeks, often alongside other actives. These study methods show what was tested, not what you should use.
The clearest routine is from the Patil trial, which used 2% cream once daily at night for 16 weeks (Patil et al., 2025). The Lim abstract doesn't report how often the gel was applied (Lim, 1999). No human study in the abstracts we reviewed compares kojic acid strengths or identifies when it starts to work.
Kojic acid is often sold or studied with other brighteners. A laser trial paired it with tranexamic acid and niacinamide, and our guide to tranexamic acid for skin covers that ingredient's larger evidence base (Park et al., 2022). No study in the abstracts we reviewed tests layering separate kojic acid, tranexamic acid or vitamin C products, so they don't support any layering order.
Sun protection matters whichever active you use. The 2026 consensus calls broad-spectrum sunscreen essential for everyone with melasma (Sarkar et al., 2026), and our SPF 30 vs 50 guide explains how the numbers differ. Evidence: Limited.
Where the evidence stops
- Kojic acid alone is barely tested in the trials we reviewed. Most of those trials involve combinations, and the main standalone arm had no placebo group.
- Trials are small and short. The main studies enrolled 25 to 72 people and ran for about 12 to 16 weeks.
- Direct comparisons are scarce in the abstracts we reviewed. None compares kojic acid, hydroquinone and arbutin head to head, though cited reviews list older studies comparing kojic acid products with hydroquinone that we didn't assess.
- The safety numbers need updating. The key allergy data date from the 1990s, and we can't estimate how often allergy occurs among all users.
- Safe-use levels are unclear in practice. The 2010 safety assessment names both 2% and a level below 1%, while the trials we reviewed commonly used 2%.
- Other dark spots lack direct data. No trial in the abstracts we reviewed tests kojic acid alone on sun spots or post-inflammatory hyperpigmentation.
- New delivery systems are unproven. Nanocarrier formulas lack clinical validation and have limited safety data (Elbekbashy et al., 2026).
FAQ
What does kojic acid do for skin?
Kojic acid inhibits tyrosinase, the enzyme that drives melanin production. In skin care, it is mainly used to fade melasma and other hyperpigmentation, and the human trials we reviewed mostly tested it alongside other active ingredients.
Does kojic acid work for melasma?
Probably, but the effect is often hard to separate from other ingredients. A 2023 meta-analysis found kojic acid lowered melasma scores, and a 12-week trial of 40 women found that adding 2% kojic acid to a glycolic acid and hydroquinone gel improved results. A separate 16-week trial of 2% kojic acid cream without a placebo group reported only a 10% drop in mMASI score.
Is kojic acid better than hydroquinone?
The evidence does not show that. A 2023 meta-analysis found comparable melasma results with less irritation for kojic acid than for hydroquinone-containing combinations, but the comparison was indirect. A 2026 expert consensus still calls supervised hydroquinone-based triple combination cream the gold standard and lists kojic acid as an alternative.
Is arbutin the same as kojic acid?
No. Kojic acid is a fungal product, while arbutin is a compound of hydroquinone and glucose. A 2021 review advises caution with arbutin products because hydroquinone may be generated during use, and a lab paper states that arbutin can break down under temperature stress, UV light or acidic dilution.
Can kojic acid cause an allergic reaction?
Yes. In a Japanese patch-test study, 5 of 8 kojic acid users with suspected cosmetic dermatitis reacted to kojic acid and to their own products containing 1% kojic acid. Their facial dermatitis began 1 to 12 months after they started the products, so a product used without problems at first can still cause a reaction later.
What percentage of kojic acid is used in studies?
Three of the main melasma trials we reviewed used 2% kojic acid. A 2010 expert safety assessment said human sensitization data supported 2% in leave-on cosmetics, yet it concluded that kojic acid is safe up to a level below 1%.
How long does kojic acid take to work?
No study in the abstracts we reviewed pinpoints when kojic acid starts to work. The main trials ran for 12 to 16 weeks, and a 16-week trial of 2% kojic acid cream reported a modest 10% drop in mMASI score.
Does kojic acid help sun spots or post-acne marks?
No trial in the abstracts we reviewed tests kojic acid alone on sun spots or post-inflammatory hyperpigmentation. A 2020 review includes kojic acid among cosmeceuticals for facial hyperpigmentation, but its abstract gives no kojic-specific result for those conditions.
References
- Elbekbashy MA, et al. Kojic Acid as a Natural Hypopigmenting Agent: Biological Activities, Delivery Challenges, and Nanotechnology-Based Strategies. Pharmaceutics. 2026. Narrative review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/42654049/
- Zilles JC, et al. Biological activities and safety data of kojic acid and its derivatives: A review. Exp Dermatol. 2022. Review; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/35960194/
- Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999. Randomized split-face trial, n=40 Chinese women, 12 weeks; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/10417583/
- Zachary CM, et al. Kojic Acid for Melasma: Popular Ingredient in Skincare Products. Skinmed. 2020. Journal article discussing the background and available studies; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/33160435/
- Searle T, et al. The top 10 cosmeceuticals for facial hyperpigmentation. Dermatol Ther. 2020. Review; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/32720446/
- Burnett CL, et al. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol. 2010. Expert panel safety assessment; PubMed tags it as non-US-government support; funder not named. Lead author's affiliation: Cosmetic Ingredient Review. https://pubmed.ncbi.nlm.nih.gov/21164073/
- Chang YF, et al. Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis. J Cosmet Dermatol. 2023. Meta-analysis, 45 efficacy studies (2,359 patients) and 55 safety studies (4,539 patients); funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/36566490/
- Sarkar R, et al. Topical and Systemic Therapies in Melasma: A Systematic Review. Indian Dermatol Online J. 2023. Systematic review, 174 randomized or controlled trials; no conflicts of interest. https://pubmed.ncbi.nlm.nih.gov/38099013/
- González-Molina V, et al. Topical Treatments for Melasma and Their Mechanism of Action. J Clin Aesthet Dermatol. 2022. Systematic review, 80 papers; no relevant conflicts reported. https://pubmed.ncbi.nlm.nih.gov/35642229/
- Sarkar R, et al. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2026. Delphi consensus, panel of 38 dermatologists from 11 countries; Galderma India funding. https://pubmed.ncbi.nlm.nih.gov/40996222/
- Suliman RS, et al. Emerging topical therapies for melasma: a comparative analysis of efficacy and safety. J Dermatolog Treat. 2025. Comparative review; n and funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/41307217/
- Hollinger JC, et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018. Systematic review, 30 clinical studies; no funding and no conflicts. https://pubmed.ncbi.nlm.nih.gov/29552273/
- Patil R, et al. Comparison of the Effectiveness and Safety of 5% Cysteamine and 2% Kojic Acid Creams in the Treatment of Melasma in Indian Adult Females. Cureus. 2025. Open-label randomized trial, n=72 women, 16 weeks; Glenmark provided materials and analysis and manuscript support, 4 authors were Glenmark employees and 1 worked for Mascot Spincontrol India. https://pubmed.ncbi.nlm.nih.gov/40296942/
- Tantanasrigul P, et al. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study. J Cosmet Dermatol. 2025. Split-face randomized pilot, n=30, 12 weeks plus 4-week follow-up; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/39555866/
- Park SJ, et al. Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: A single center, prospective, split-face trial. Dermatol Ther. 2022. Prospective split-face trial, n=25, 5 sessions at 2-week intervals plus 4-week follow-up; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/34962047/
- Nakagawa M, et al. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995. Patch-test study with case reports, n=220 women, 1 year; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/7720390/
- Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel). 2021. Review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/34356362/
- Khadivi Y, et al. Quantification of Arbutin and its degradation products, hydroquinone and p-Benzoquinone, in hyperpigmentation topical formulation: Effect of extraction procedure and interference assessment. J Pharm Biomed Anal. 2024. Laboratory analytical study; no competing interests declared. https://pubmed.ncbi.nlm.nih.gov/38763108/
- Saeedi M, et al. A comprehensive review of the therapeutic potential of α-arbutin. Phytother Res. 2021. Review; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/33724594/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Persistent dark patches should be checked by a dermatologist. A rash after using a product is worth discussing with a clinician.